Key facts
- It has raised $6.1M; the latest was Seed Round ($5.5M) in Dec 2025.
- Notable investors include Creative Destruction Lab, University of Toronto Entrepreneurship, Foothill Ventures, rpv, Jumpspace Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Neuraworx
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuraworx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuraworx
Developer of medical devices and equipment company designed for the prevention and treatment of central nervous system (CNS) disorders. The company's Cerebrovascular Pacing system is used to represent a paradigm shift in neurodegenerative disease management by targeting a fundamental physiological process, the brain's natural waste clearance mechanism, enabling patients with enhanced blood and cerebrospinal fluid flow through the brain to remove waste and improve brain health.
- Sector
- Healthcare
- HQ
- Excelsior, MN, United States
- Founded
- 2021
- Employees
- 5
- Website
- neuraworx.com/
- Ownership
- Privately Held (backing)
Neuraworx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuraworx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuraworx in its N-PORT filings yet. We sweep new filings monthly.